Cite
Guo L, Parker DL, Zang Y, et al. Discovery and Optimization of a Novel Triazole Series of GPR142 Agonists for the Treatment of Type 2 Diabetes. ACS Med Chem Lett. 2016;7(12):1107-1111doi: 10.1021/acsmedchemlett.6b00314.
Guo, L., Parker, D. L., Zang, Y., Sweis, R. F., Liu, W., Sherer, E. C., Buist, N., Terebetski, J., Kelly, T., Bugianesi, R., Priest, B. T., Dingley, K. H., Li, X., Mitelman, S., Salituro, G., Trujillo, M. E., Pachanski, M., Kirkland, M., Powles, M. A., Eiermann, G. J., Feng, Y., Shang, J., Howard, A. D., Ujjainwalla, F., Sinz, C. J., Debenham, J. S., Edmondson, S. D., Nargund, R. P., Hagmann, W. K., & Li, D. (2016). Discovery and Optimization of a Novel Triazole Series of GPR142 Agonists for the Treatment of Type 2 Diabetes. ACS medicinal chemistry letters, 7(12), 1107-1111. https://doi.org/10.1021/acsmedchemlett.6b00314
Guo, Liangqin, et al. "Discovery and Optimization of a Novel Triazole Series of GPR142 Agonists for the Treatment of Type 2 Diabetes." ACS medicinal chemistry letters vol. 7,12 (2016): 1107-1111. doi: https://doi.org/10.1021/acsmedchemlett.6b00314
Guo L, Parker DL, Zang Y, Sweis RF, Liu W, Sherer EC, Buist N, Terebetski J, Kelly T, Bugianesi R, Priest BT, Dingley KH, Li X, Mitelman S, Salituro G, Trujillo ME, Pachanski M, Kirkland M, Powles MA, Eiermann GJ, Feng Y, Shang J, Howard AD, Ujjainwalla F, Sinz CJ, Debenham JS, Edmondson SD, Nargund RP, Hagmann WK, Li D. Discovery and Optimization of a Novel Triazole Series of GPR142 Agonists for the Treatment of Type 2 Diabetes. ACS Med Chem Lett. 2016 Oct 12;7(12):1107-1111. doi: 10.1021/acsmedchemlett.6b00314. eCollection 2016 Dec 08. PMID: 27994747; PMCID: PMC5150677.
Copy
Download .nbib